

Open Peer Review on Qeios

Autologous IL-2-expressing B-CLL Vaccine

National Cancer Institute

Source

National Cancer Institute. <u>Autologous IL-2-expressing B-CLL Vaccine</u>. NCI Thesaurus. Code C118851.

A cancer vaccine consisting of autologous, B-chronic lymphocytic leukemia (B-CLL) cells harvested from a patient and transduced ex vivo with an adenoviral vector encoding the gene for the human cytokine interleukin-2 (IL-2), with potential immunostimulating and antineoplastic activities. Upon reintroduction into the patient, the autologous IL-2-expressing B-CLL vaccine expresses IL-2, stimulates natural killer (NK) cells, and may enhance the cytotoxic T-lymphocyte (CTL) immune response against the patient's B-CLL cells.

Qeios ID: O4NM4G · https://doi.org/10.32388/O4NM4G